This is a type of cancer that starts in nerve tissue. It's a rare cancer that can develop from other nerve tissue tumors. It's considered moderately serious, meaning it's not very aggressive but can grow and spread if not treated.
Every report comes from a Lived member, sent anonymously.
Have you had Surgery for Ganglioneuroblastoma?
Ganglioneuroblastoma is a rare tumor of developing nerve tissue, found mostly in young children. It belongs to the same family as neuroblastoma, a childhood cancer of immature nerve cells, and ganglioneuroma, a benign tumor made of fully mature nerve cells. Ganglioneuroblastoma sits between the two: it contains both immature cells (neuroblasts) and more mature nerve cells, and how it behaves depends largely on how those cells are arranged. The tumor usually grows along the chain of nerves that runs beside the spine, from the neck to the pelvis, or in an adrenal gland on top of a kidney. Many cause no symptoms and are found by chance on a scan. Others are noticed as a lump in the belly, chest or neck, or because the tumor presses on nearby structures. A tumor in the neck or upper chest can cause Horner syndrome (a droopy eyelid, a smaller pupil and less sweating on one side of the face), and a tumor beside the spine can press on the spinal cord. Pathologists separate two main types. In the intermixed type, the immature cells are scattered through mostly mature tissue; this type behaves much more like a benign tumor and has an excellent outlook when it has not spread. In the nodular type, there are distinct clumps of immature cells that can act like neuroblastoma. Some nodular tumors have favorable features, while others are aggressive and may already have spread when they are found.
Like neuroblastoma, ganglioneuroblastoma starts from cells that normally mature into the nerves controlling automatic body functions such as heart rate and blood pressure. For reasons that are mostly unknown, some of these cells stop maturing on schedule and form a tumor. Gene changes inside the tumor drive this, but in most children nothing the family did or could have avoided caused it. A small number of neuroblastic tumors run in families. The most common inherited cause is a change in a gene called ALK, and children with certain rare genetic conditions may be offered regular screening. When there is a family history of these tumors, genetic counseling can help clarify whether testing makes sense. Ganglioneuroblastoma in adults is very rare and has been described mainly in individual case reports.
Evaluation usually starts with imaging. Ultrasound, CT or MRI shows where the tumor is, how large it is and whether it wraps around important blood vessels or extends toward the spinal canal; MRI is used when a tumor lies close to the spine. Urine tests measure breakdown products of stress hormones (catecholamines) that these tumors often release, and raised levels support the diagnosis. The diagnosis is confirmed by examining tumor tissue under a microscope, either from a biopsy or after the tumor is removed. This step decides whether the tumor is the intermixed or nodular type, and the laboratory may also test the tumor's genes, including whether a gene called MYCN is amplified, a feature linked to more aggressive disease. A small biopsy does not always capture the whole tumor. In one large UK study of tumors first diagnosed by biopsy as intermixed ganglioneuroblastoma or ganglioneuroma, about 1 in 8 turned out to be a more aggressive type once the full tumor was examined, which is one reason doctors weigh the biopsy result alongside the scans. To check for spread, doctors may order an MIBG scan, in which a small amount of a radioactive tracer that collects in this kind of tumor is injected and then imaged, and sometimes bone marrow tests. Together, the tumor type, gene results, extent of spread and the child's age place the tumor into a risk group, and the risk group guides treatment.
Treatment follows the tumor's risk group, and it ranges from careful watching to intensive cancer therapy. Care is best planned by a pediatric cancer team with experience in neuroblastoma. For intermixed ganglioneuroblastoma that has not spread, the main options are surgery to remove the tumor or a period of active observation with regular scans. Surgery has long been the standard, and complete removal is usually possible, but operations near major vessels or nerves carry a real risk of complications. Observation avoids or delays that risk. In a large UK study, overall survival was 98% whichever approach was used, and about a third of children who were watched later needed surgery, most often because the tumor grew. Observation may also be less suitable when the biopsy leaves doubt about the tumor type. For nodular ganglioneuroblastoma, treatment depends on whether the nodules have favorable features and whether the tumor has spread. Localized tumors with favorable features are often treated with surgery alone. Tumors with unfavorable features, or those that have spread, are treated much like neuroblastoma in the same risk group. Intermediate-risk treatment usually means several cycles of chemotherapy, often before surgery. High-risk treatment is intensive and lasts many months, combining chemotherapy, surgery, radiation, high-dose chemotherapy with a stem cell transplant, immunotherapy and a vitamin A-related medicine (isotretinoin). Clinical trials are a common part of care for children with neuroblastic tumors.
The outlook varies more with the tumor type than with the name. Children with intermixed tumors, or nodular tumors with favorable features, that have not spread usually do very well, and in a large North American series of these favorable tumors there were no deaths from the tumor. For these children, life after surgery or during observation is mostly ordinary, with follow-up scans and urine tests for several years to confirm the tumor is not growing or returning. Nodular tumors with unfavorable features are a different situation. About half have already spread when found, and the chance of cure depends strongly on how far the disease has spread. Children treated on high-risk plans face months of hospital-based treatment, time away from school and activities, and heavy demands on the whole family. Children who receive chemotherapy or radiation need long-term survivorship follow-up, because some effects appear years later. Depending on the treatment, these can include hearing loss, problems with bone growth or tooth development, changes in learning or memory, and a higher risk of a second cancer later in life. Children treated with surgery alone or observation avoid most of these risks.
See your child's doctor about a lump or swelling in the belly, chest or neck, bone pain that does not settle, or a newly droopy eyelid with a smaller pupil on one side. If your child is being observed rather than treated, keep scheduled scans and report any new symptoms rather than waiting for the next visit. Call the care team promptly for severe, persistent watery diarrhea, which some of these tumors cause by releasing a hormone, or for rapid jerky eye movements, sudden jerking of the limbs or new unsteadiness, which can signal a rare immune reaction to the tumor. New weakness in the legs, trouble walking or standing, or loss of movement in any part of the body can mean the tumor is pressing on the spinal cord. This needs emergency care right away, because prompt treatment can protect nerve function.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Ganglioneuroblastoma is like, what's helped you, or ask the community a question.